Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

Commenting on our previous paper on the discordance between high pCR and final breast conserving surgery in the NeoALTTO trial, Berry et al made some hypotheses that might have influenced surgeons when deciding on the type of surgery. Here, we restate the importance of multidisciplinary discussions, especially considering how systemic therapy has improved treatment outcome.